The study, which is the first to show that a multi-strain vaginal synbiotic can establish a protective vaginal environment, will be presented at the Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG)
The data demonstrate that VS-01™ successfully cultivates a vaginal microbiome dominated by Lactobacillus crispatus, reduces harmful microbes, and combats vaginal dysbiosis
These results underscore the potential of the vaginal microbiome and microbiome-directed innovations to redefine standards of care in women’s health
BOSTON, Aug. 1, 2024 /PRNewswire/ — Seed Health will present new clinical data on its flagship vaginal microbiome innovation, VS-01™ Vaginal Synbiotic, at the upcoming 2024 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. Data from a randomized, placebo-controlled clinical trial demonstrated the superior efficacy of VS-01™ in cultivating a stable and healthy vaginal microbiome. The synbiotic successfully established a protective environment dominated by Lactobacillus crispatus and inhibited harmful microbes associated with vaginal dysbiosis and inflammation. These findings highlight the transformative potential of proactive, preventive care centered on the vaginal microbiome, shifting the focus from traditional symptom management to maintaining a balanced and resilient vaginal ecology.
A landmark 2012 study from vaginal microbiome researcher Jacques Ravel, Ph.D., demonstrated that the most stable and optimal vaginal microbiome is characterized by a dominance of the bacterium Lactobacillus crispatus, which plays a protective role in maintaining vaginal health. However, everyday factors such as menstruation, sexual activity, exercise, stress, contraceptives, and cleansers can deplete the abundance of L. crispatus, leading to dysbiosis and related gynecological, urogenital, and obstetric conditions. Despite this, there have been no consumer innovations nor microbiome-directed solutions clinically validated to cultivate this optimal vaginal ecology.
“Over more than two decades of research, we have elucidated the critical role of Lactobacillus crispatus in maintaining a protective and stable vaginal microbiome and identified specific strains that are particularly effective at promoting vaginal health,” explained Dr. Jacques Ravel, lead researcher. “VS-01™ was formulated using a consortia design with three proprietary strains of L. crispatus to successfully establish an L. crispatus-dominant vaginal microbiome, marking a significant milestone in the field and advancement for women’s health.”
“VS-01™ was developed to set a new standard in vaginal care,” stated Sheri Simmons, Ph.D., VP of Discovery at Seed Health. “Our latest clinical findings underscore the potential of proactive care centered on the vaginal microbiome. By modulating the vaginal ecology, VS-01™ offers a new approach to support long-term vaginal health.” Dr. Simmons will lead the presentations of two abstracts on VS-01™ at IDSOG.
IDSOG Presentation Highlights
Poster Presentation: A Novel Multi-strain Vaginal Synbiotic is Effective in Inhibiting Microbes Associated with Vaginal Dysbiosis, Inflammation, and Mucus Barrier DegradationDate and Time: Friday, August 2 at 1:30 PM PT
This study assessed the impact of VS-01™ on vaginal dysbiosis, inflammation, and mucus barrier integrity. Key findings include:
These presentations will detail the methodology and results from the two clinical abstracts, underscoring the transformative potential of microbiome science to enhance women’s health and well-being.
“The data presented at IDSOG showcases the rigorous scientific approach we bring to probiotics and microbiome-directed solutions,” stated Dirk Gevers, Ph.D., Chief Scientific Officer at Seed Health. “By evaluating biomarkers of vaginal health and conducting deep microbiome sequencing, we have validated the clinical benefits of VS-01™ to clearly distinguish it from other vaginal health solutions.”
About Seed Health
Seed Health is a microbiome science company pioneering innovations in probiotics and living medicines to impact human and planetary health. Founded to realize the potential of the microbiome, our platform enables the translation of breakthrough science across a portfolio targeting health outcomes from infancy to aging. Our consumer innovations are commercialized under Seed®, an award-winning, science-first brand known for clinically validated innovations in probiotics, including DS-01® Daily Synbiotic and PDS-08® Pediatric Daily Synbiotic. Our pipeline encompasses both indication-specific and preventive applications for gastrointestinal and digestive health, women’s health, skin, pediatrics, brain health, metabolic function, and healthy aging. Our environmental research is conducted under SeedLabs, which was founded to advance novel bacterial interventions to enhance biodiversity and restore ecosystems impacted by human activity.
Press Contact[email protected]
SOURCE Seed Health
